Research Topics
| Philip T NinanSummaryAffiliation: Emory University Country: USA Publications
| Collaborators
|
Detail Information
Publications
High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trialPhilip T Ninan
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1841 Clifton Road, Atlanta, GA 30329, USA
J Clin Psychiatry 67:15-22. 2006..To evaluate the efficacy and safety of high-dose sertraline for patients with obsessive-compulsive disorder (OCD) who failed to respond to standard sertraline acute treatment...- Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatiguePhilip T Ninan
Department of Psychiatry, Emory University School of Medicine, 1841 Clifton Road, Suite 400 North, Atlanta, GA 30329, USA
J Clin Psychiatry 65:414-20. 2004..This open-label study evaluated the efficacy and safety of modafinil treatment initiated with an SSRI in patients with MDD and fatigue... - Obsessive-compulsive disorder: implications of the efficacy of an SSRI, paroxetinePhilip T Ninan
Department of Psychiatry, Emory University, Atlanta, GA 30329, USA
Psychopharmacol Bull 37:89-96. 2003..Because of their safety and beneficial adverse-event profile, the SSRIs have become the leading choice in the pharmacological management of OCD... - Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled studyBoadie W Dunlop
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, GA 30307, USA
J Clin Psychopharmacol 27:614-9. 2007..Previous studies suggest that adjunctive modafinil treatment provides benefit for patients with depression with significant sleepiness and fatigue... - Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combinationJohn Zajecka
Department of Psychiatry, Rush-Presbyterian-St. Luke's Medical Center, 1725 W. Harrison Street, Suite 955, Chicago, IL 60612, USA
J Clin Psychiatry 63:709-16. 2002..Treatment with nefazodone, CBASP, and combined treatment improved sexual interest/satisfaction, with greatest improvement observed with combined treatment... - Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT StudyJames H Kocsis
Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
J Clin Psychiatry 68:1014-23. 2007..To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression... - Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depressionMichael E Thase
Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, PA 15213 2593, USA
J Clin Psychiatry 63:493-500. 2002..As nefazodone-mediated blockade of serotonin-2 receptors may directly relieve insomnia associated with depression, we examined the more specific effects of CBASP and nefazodone, singly and in combination, on sleep disturbances... 
Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP TrialJames H Kocsis
Department of Psychiatry, Weill Cornell Medical College, 1300 York Ave, New York, NY 10065, USA
Arch Gen Psychiatry 66:1178-88. 2009..Previous studies have found that few chronically depressed patients remit with antidepressant medications alone...- Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is notAlan F Schatzberg
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305 5717, USA
Arch Gen Psychiatry 62:513-20. 2005..Although various strategies are available to manage nonresponders to an initial treatment for depression, no controlled trials address the utility of switching from an antidepressant medication to psychotherapy or vice versa... - Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood traumaCharles B Nemeroff
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322
Proc Natl Acad Sci U S A 100:14293-6. 2003..Our results suggest that psychotherapy may be an essential element in the treatment of patients with chronic forms of major depression and a history of childhood trauma... - The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depressionA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9086, USA
Biol Psychiatry 54:573-83. 2003..The QIDS-SR(16) has highly acceptable psychometric properties, which supports the usefulness of this brief rating of depressive symptom severity in both clinical and research settings... - REVAMP - Research Evaluating the Value of Augmenting Medication with Psychotherapy: rationale and designMadhukar H Trivedi
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA
Psychopharmacol Bull 41:5-33. 2008.... - Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combinationPhilip T Ninan
Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30329, USA
J Clin Psychiatry 63:434-41. 2002..Among patients with a concurrent anxiety disorder, nefazodone. either alone or in combination with CBASP, improves anxiety symptoms faster than CBASP alone, independent of depressive symptom reduction... - The state of knowledge of chronic depressionAlan J Gelenberg
Department of Psychiatry, Arizona Health Sciences Center, Tucson, AZ, USA
J Clin Psychiatry 67:179-84. 2006 - A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorderEric Hollander
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
J Clin Psychiatry 64:640-7. 2003.... 
A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disordersMark S George
Department of Psychiatry, Medical University of South Carolina, Charleston, South Carolina 29425, USA
Brain Stimul 1:112-21. 2008....- Report by the ACNP Task Force on response and remission in major depressive disorderA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
Neuropsychopharmacology 31:1841-53. 2006..Research to evaluate these recommendations empirically is needed... - An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorderMichael E Thase
Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
CNS Spectr 14:144-54. 2009..To assess the efficacy of desvenlafaxine (administered as desvenlafaxine succinate) in outpatients with major depressive disorder... - Tiagabine for social anxiety disorderBoadie W Dunlop
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30329, USA
Hum Psychopharmacol 22:241-4. 2007..Results of this pilot study suggest that tiagabine may be an option for the treatment of patients with SAD. Larger, controlled studies are required to fully elucidate the potential of tiagabine for the treatment of SAD... - The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorderSteven J Garlow
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
J Psychiatr Res 46:1406-13. 2012..To determine whether the combination of triiodothyronine (T3) plus sertraline at treatment initiation confers greater antidepressant efficacy than sertraline plus placebo in patients with major depressive disorder... - Recovery and subsequent recurrence in patients with recurrent major depressive disorderBoadie W Dunlop
Emory University School of Medicine, 1256 Briarcliff Road, Building A, 3rd Floor, Atlanta, GA 30322, USA
J Psychiatr Res 46:708-15. 2012..We conclude that protection against recurrence derives from the degree and duration of recovery, particularly for patients maintained on antidepressant medication... - New developments in the neurobiological basis of anxiety disordersJack M Gorman
Department of Psychiatry, Columbia University, New York, New York 10032, USA
Psychopharmacol Bull 36:49-67. 2002.... - Use of dialectical behavior therapy in borderline personality disorder: a view from residencyBinali Sharma
Emory University School of Medicine, Atlanta, Georgia, USA
Acad Psychiatry 31:218-24. 2007..The authors describe the use of dialectical behavior therapy (DBT) in treating borderline personality disorder during psychiatry residency, and assess the status of DBT education within psychiatry residencies in the United States... - Social anxiety disorder and the neurobiology of social relationshipsPhilip T Ninan
Department of Psychiatry and Behavioral Sciences, Mood and Anxiety Disorders Program, Emory University School of Medicine, Atlanta, GA, USA
Psychopharmacol Bull 36:94-101. 2002..Understanding the neural circuitry mediating social relationships and its role in the threat response in SAD may be important for the development of new treatments for this disorder... - New insights into the diagnosis and pharmacologic management of generalized anxiety disorderPhilip T Ninan
Mood and Anxiety Disorders Program, Emory University School of Medicine in Atlanta, GA, USA
Psychopharmacol Bull 36:105-22. 2002..Some antidepressants have been shown to better facilitate remission. This article will summarize evidence for the clinical utility of pharmacotherapeutic agents commonly used in the treatment of GAD... - Neurobiology and etiology of panic disorderPhilip T Ninan
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA
J Clin Psychiatry 66:3-7. 2005..The lessons learned can guide the delivery of treatments to enhance the likelihood of achieving remission and the discovery of novel treatments for panic disorder... - New goals in the treatment of depression: moving toward recoveryMichael E Thase
Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Psychopharmacol Bull 36:24-35. 2002..Compared with TCAs, the better safety profile of venlafaxine has established the drug as a more appropriate first-line treatment option... - A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sitesBoadie W Dunlop
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
Neuropsychopharmacology 37:2830-6. 2012..24, p=0.034) and response rate (β=2.26, p=0.035). Including a higher proportion of academic sites may increase the ability to detect differences between active drug and placebo in clinical trials of major depressive disorder... - Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combinationRobert M A Hirschfeld
Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, Texas 77555 0188, USA
Biol Psychiatry 51:123-33. 2002..This study compared efficacy of nefazodone, psychotherapy, and their combination in improving psychosocial functioning in chronically depressed outpatients... - The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phasesMartin B Keller
Department of Psychiatry and Human Behavior, Brown University, Providence, RI 02906, USA
J Clin Psychiatry 68:1246-56. 2007..To report second-year results from the 2-year maintenance phase of a long-term study to evaluate the efficacy and safety of venlafaxine extended release (ER) in preventing recurrence of depression... - The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phasesMartin B Keller
Brown University, Providence, Rhode Island 02906, USA
Biol Psychiatry 62:1371-9. 2007..We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment... - Integrating neurobiology and psychopathology into evidence-based treatment of social anxiety disorderMichael R Liebowitz
Anxiety Disorders Clinic, New York State Psychiatric Institute, New York City, USA
CNS Spectr 10:suppl13 1-11; discussion 12-3; quiz 14-5. 2005..The prevalence, rates of recognition and treatment, patterns of comorbidity, quality-of-life issues, and natural history of SAD are discussed as well as pharmacologic and psychosocial treatment strategies for SAD... - Psychosocial context of antidepressant responseBoadie W Dunlop
Biol Psychiatry 57:314; author reply 314-5. 2005 - Selective publication of antidepressant trialsPhilip T Ninan
N Engl J Med 358:2181; author reply 2181-2. 2008